Forte Biosciences (FBRX) Capital Expenditures (QoQ) (2016 - 2025)
Powered by 
Analysis
Forte Biosciences (FBRX) Capital Expenditures (QoQ) (2016 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 96.77% |
| Mar 31, 2024 | -64.71% |
| Dec 31, 2023 | -58.54% |
| Dec 31, 2019 | 148.37% |
| Sep 30, 2019 | -248.39% |
| Jun 30, 2019 | -6.77% |
| Mar 31, 2019 | -71.82% |
| Dec 31, 2018 | -23.75% |
| Sep 30, 2018 | -5.78% |
| Jun 30, 2018 | 198.64% |
| Mar 31, 2018 | -30.82% |
| Dec 31, 2017 | 77.65% |
| Sep 30, 2017 | 70.48% |
| Jun 30, 2017 | 98.11% |
| Mar 31, 2017 | 430.00% |
| Dec 31, 2016 | -93.75% |
| Sep 30, 2016 | -34.96% |
| Jun 30, 2016 | 125.69% |